Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 238 of 6351
-
Engineered immune cells take aim at childhood leukemia
Disease control Recruiting nowThis is a gene transfer study for patients with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) that has come back or has not gone away after treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cance…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo hopes to tame rare muscle disease in kids
Disease control Recruiting nowThis is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
Phase 3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowPhase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
Disease control Recruiting nowThis is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy.…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Weekly shot could help kids lose weight – major trial underway
Disease control OngoingThis study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the c…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
New drug duo aims to shrink advanced kidney tumors
Disease control CompletedThis is a Phase II, open-label trial to evaluate the efficacy and safety of AK104 monotherapy or AK104 in combination with axitinib as a first-line treatment for advanced/metastatic renal cell carcinoma (RCC). There are two parts in this trial. In part 1 of this study, subjects w…
Phase 2 • Sponsor: Akeso • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New scan could spot prostate cancer earlier and more accurately
Diagnosis PausedThe diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to provide the molecular imaging of the whole body an…
Sponsor: Primo Biotechnology Co., Ltd • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Could a common diabetes drug boost chemotherapy against pancreatic cancer?
Disease control By invitation onlyThe purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a single Immune-Targeting drug quiet an autoimmune kidney disease?
Disease control OngoingTo confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
Phase 3 • Sponsor: Shoichi Maruyama MD PhD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail aims to fight rare cancer
Disease control Recruiting nowThis study is a prospective open-label, single-arm, single-center clinical study. Patients with neuroendocrine carcinoma who had not previously received standard therapy were enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligi…
Phase 1/2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Blood test may spot cancer recurrence months before standard scans
Diagnosis Recruiting nowColorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to rise. Patients who receive treatment in the early stag…
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 26, 2026 18:08 UTC
-
New combo pill and injection aims to control leukemia in frail patients
Disease control Recruiting nowThe purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \[IDH1m\]) and canno…
Phase 3 • Sponsor: Servier Affaires Médicales • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could breast cancer patients skip extra immunotherapy? major trial aims to find out
Disease control Recruiting nowThis phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after …
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Triple threat before surgery: could a new combo wipe out stomach cancer cells?
Disease control CompletedGastric cancer is the third leading cause of death due to cancer worldwide. Although the consensus on the surgical treatment has resulted in the improvement of curative effect during the past decades, controversies remained for the perioperative therapy of gastric cancer, especia…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New vaccine duo takes on deadly skin cancer
Disease control OngoingThe researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can a custom sound map unlock better hearing for cochlear implant users?
Disease control CompletedThe current standard of care approach for programming cochlear implants uses a generalized pitch-map for all patients. This approach fails to account for individualized inner ear anatomy. As a result, many cochlear implant recipients experience place-pitch mismatch. We have recen…
Sponsor: Western University, Canada • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New daily pill could help millions shed pounds and improve health
Disease control OngoingThis study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Part…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail targets genetic weakness in rare cancer
Disease control Recruiting nowThe goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-10…
Phase 1/2 • Sponsor: Michael J. Dennis, MD • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedPhase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowDoctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for t…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC